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English summary 
Insufficient analgesia after surgery increases the risk of developing chronic 
postoperative pain, affecting the quality of life and is associated with large 
economic losses. Opioids are the drugs of choice for moderate to severe pain and 
are used by many chronic pain patients in Denmark. However, the analgesic effect 
varies widely between individuals, resulting in inadequate response for 
approximately one-third of patients. Biomarkers of opioid analgesia are therefore 
needed in order to personalize and optimize the treatment. 
The objective of this PhD thesis was to investigate electroencephalography (EEG) 
as a biomarker for analgesic response to opioids. This included establishing changes 
in the biomarker during pain, the reliability of the biomarker and investigating if the 
signal contains information which could help determine if a given patient will 
respond to treatment. 
Data from one experimental study and one clinical observational study formed the 
basis for this PhD thesis. The first study was a placebo-controlled experiment in 
healthy volunteers. EEG during rest and cold pain (hand immersed in 2°C water for 
two minutes) was recorded prior and 60 minutes after administration of 30 mg oral 
morphine. Paper I explored reliability and dynamics of spectral indices during rest 
and cold pain. Paper II investigated whether EEG could be used to predict the 
analgesic response to morphine. The second study was an observational survey of 
patients undergoing total hip replacement surgery and formed the basis for paper 
III. Patients were examined prior to surgery where EEG was also recorded. Pain 
was assessed in the first 24 hours after surgery to determine analgesic response 
from combined oxycodone and piritramide treatment. 
The main finding from paper I was that the spectral indices derived from EEG are 
reliable over time, which is essential for a biomarker to be clinically viable. 
Furthermore, the theta (4 – 8 Hz) band correlated both overall and dynamically with 
pain ratings, suggesting close involvement in the pain experience. In paper II it was 
possible to predict which subjects would respond to morphine with an accuracy of 
72% using EEG spectral indices during cold pain as baseline measurement. Resting 
EEG on the other hand, could not predict the morphine response. Paper III further 
confirmed these results by predicting response to oxycodone and piritramide after 
surgery with an accuracy of 65%, again this was only possible using EEG during 
cold pain.  
In conclusion, EEG appears suitable as an objective biomarker for analgesic 
response to opioids. It is both reliable over time and contains information which can 
assist in determining if a given opioid is suitable for a patient. This represents the 
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first step towards a personalized medicine algorithm based on EEG.  Future clinical 
studies should investigate the EEG further in more clinical studies. Another venue 
of interest would be to combine the EEG with other biomarkers, such as genetics, 
quantitative sensory testing and psychological questionnaires.  
ix 
Dansk resumé 
Utilstrækkelig smertebehandling efter operationer øger risikoen for udvikling af 
kronisk smerte, nedsætter livskvaliteten for patienten og er forbundet med store 
økonomiske omkostninger for samfundet. Opioider er den foretrukne medicin til at 
behandle moderat til svære smerter og bliver brugt at mange patienter med kronisk 
smerte i Danmark.  Der er imidlertidig stor forskel mellem individer på den 
smertestillende effekt af  opioider, hvilket resulterer i utilstrækkelig 
smertebehandling i omkring en tredjedel af patienterne. Derfor er der behov for 
biomarkører for opioiders effekt for at målrette behandlingen mod den enkelte 
patient. 
Formålet med dette ph.d.-projekt var at undersøge elektroencefalografi (EEG) som 
en biomarkør for smertestillende effekt af opioider. Dette inkluderede etablering af 
biomarkørens ændringer under smerte, dens pålidelighed samt undersøgelse af om 
signalet indeholder information som kan bruges til at forudsige om en patient vil 
respondere på behandlingen. 
Data fra et eksperimentelt og et klinisk studie danner basis for  ph.d.-projektet. Det 
første studie var et placebo-kontrolleret eksperiment på raske frivillige. Der blev 
optaget EEG i hvile og under kuldesmerter (hånden nedsunket i 2˚C vand i 2 
minutter) før og 60 minutter efter oral indtagelse af 30 mg morfin. Arbejde I 
undersøgte pålidelighed og dynamik af de spektrale indeks under hvile og 
kuldesmerter. Arbejde II forsøgte at forudsige responset på morfinbehandling ud fra 
EEG. Arbejde III er baseret på det andet studie som var et klinisk observations 
studie af patienter der skulle opereres for slidgigt i hoften med en hofteprotese. 
Patienterne blev undersøgt før operationen, hvor bl.a. EEG blev optaget. 
Patienternes smerte blev vurderet de første 24 timer efter operationen for at 
bestemme  responset på kombinationsbehandling med oxycodon og piritramid.  
Hovedresultaterne  fra arbejde I var at de spektrale indeks fra EEG er pålidelige, 
hvilket er en essentiel kvalitet for en biomarkør til klinisk brug. Der blev også 
påvist en både overordnet og dynamisk sammenhæng mellem theta båndet og 
forsøgspersonernes smerte, hvilket indikerer en tæt forbindelse mellem theta (4 – 8 
Hz) båndet og oplevelsen af smerte. I arbejde II var det muligt at forudsige  hvilke 
patienter der ville respondere til morfin med 72% nøjagtighed på baggrund af EEG 
under kuldesmerter optaget før morfinindgift. EEG i hvile var derimod ikke i stand 
til at forudsige effekten af morfin. Arbejde III bekræftede disse resultater yderligere 
ved at forudsige effekten af behandling med oxycodon og piritramid med 65% 
nøjagtighed og dette var igen kun muligt ved brug af EEG under kuldesmerter. 
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EEG virker således brugbar som en biomarkør for smertestillende effekt af 
opioider. Målingen er både pålidelig og indeholder information som kan  bestemme 
sandsynligheden for at et givet opioid har effekt ved den enkelte patient. Dette er 
det første skridt på vejen mod en algoritme til personlig smertebehandling på basis 
af EEG. EEG bør undersøges i nærmere i flere kliniske studier. En yderligere 
mulighed kunne være at kombinere EEG med andre biomarkører som genetik, 
kvantitativ sensorisk undersøgelse af smertesystemet og psykologiske 
spørgeskemaer. 
xi 
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Chapter 1. Introduction 
Proper control of pain still remains a problem in treatment of postoperative pain1,2. 
Inadequate pain treatment adversely affects patients immediately following 
surgery3. Acute pain felt immediately after surgery also increases the likelihood of 
developing persistent long-term chronic pain, more than the procedure itself3,4. This 
is connected to a loss of function and quality of life5 as well as large direct and 
indirect economic costs for society6.  
Opioids are widely used as treatment for moderate-to-severe pain7, with up to 13% 
of Danish chronic pain patients in treatment8,9. Despite it wide use, the response to 
opioid analgesia is heterogeneous with approximately 30% of patients not 
responding to the treatment10. The exact mechanism that determines opioid 
responsiveness still remains elusive, but gender, age and genetic variation are 
known factors10–13. Switching to another opioid can be effective in treatment of 
patients who initially do not respond. Thus, pain control was improved from 74% to 
96% when switching non-responding patients from morphine to another opioid14. 
Personalized treatment of pain therefore shows great in optimizing treatment, by 
enabling the initial choice of the correct opioid. However, to date there is no 
accurate method for identification of opioid responders15. Several attempts have 
been made to predict the analgesic efficacy using quantitative sensory models 
(QST), but results have been conflicting between QST modalities and study 
populations16,17. Thus, there is a need for further investigations before personalized 
pain treatment is a reality15,18. 
Pain is a conscious perception arising in the brain19. Therefore, individual 
differences in brain function can also influence analgesic efficacy for the individual 
and a better understanding of these differences is needed to pave the road for 
personalized pain treatment18. Magnetic resonance imaging and positron emission 
tomography can assess brain function, but require specialized personnel and incur 
high costs both in acquisition and maintenance. Electroencephalography (EEG) is a 
more clinically feasible method due to lower costs and simplicity of the required 
equipment. EEG has previously been used to assess individual differences in brain 
function to predict the experience of pain for the individual20. However, it is 
possible that a single predictor will not enable personalized treatment, and instead 
several factors will have to be assessed simultaneously18. Machine learning enables 
such assessments and it has been shown previously to enable otherwise obscured 
findings when assessing the EEG by looking at several features at once21.  
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1.1. Hypothesis 
The hypothesizes for the PhD research project were: 1) EEG is a reliable 
measurement which is stable over time, 2) EEG contains information which can be 
used to accurately predict the outcome of opioid treatment and 3) the use of 
machine learning will improve prediction by taking into account several predictors 
at once on an invidualized level.  
1.2. Aims 
This PhD thesis took the following three-step approach for investigating 
personalized pain medicine using EEG and machine learning: 
 To investigate reliability and dynamics of the EEG during rest and cold 
pain in healthy volunteers to assess robustness of the biomarker. 
 Investigate if prediction of morphine analgesia is possible in healthy 
volunteers. 
 Predict postoperative opioid analgesia in patients undergoing total hip 
replacement surgery. 
This resulted in the following aims:  
I. To investigate the reliability of EEG over time in order to establish if the 
measurements would be sufficiently robust to use in personalized medicine 
(Paper I). 
II. Analyze dynamics of the EEG and pain ratings during cold pain to gain 
further insight into pain processing during cold pain. 
III. To establish whether the EEG during rest or tonic cold pain is the most 
suited for prediction of opioid analgesia (Paper I, II and III). 
IV. To compare a machine learning analysis approach to conventional group-
based statistics in order to investigate if more sensitive prediction can be 
achieved (Paper II and III). 
V. To explore if combination of several features in machine learning enables 
separation of responders and non-responders to morphine in healthy 
volunteers (Paper II). 
VI. To investigate if machine learning can be used to predict the analgesic 
efficacy in patients with postoperative pain (Paper III). 
 Chapter 2. The Pain System  
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Chapter 2. The Pain System 
The international association for the study of pain defines pain as “an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, 
or described in terms of such damage”. Thus, pain serves as a warning signal for the 
brain to act or risk harm to the body. Pain is most commonly triggered by activation 
of peripheral nociceptors which relay information about the noxious stimuli to the 
central nervous system (CNS)22. However, pain can also be felt in the absence of 
noxious stimuli23.  
 
2.1. Primary afferents 
Primary afferents are free nerve endings which respond to noxious stimuli and relay 
information to the CNS regarding the intensity and location of the stimulus24.  
Primary afferents are divided into three fiber categories depending on size and 
conduction velocity: 
 Aβ: Large, highly myelinated fibers which conduct signals quickly to the 
CNS. Mostly conducts signals regarding light touch and tactile information 
 Aδ: Thin, myelinated fibers, which conduct signals slower than Aβ-fibers. 
Responds to noxious chemical, mechanical and thermal stimulations 
 C: Non-myelinated fibers, responding to the same stimuli as Aδ-fibers, but 
with slower conducting velocity due to the lack of myelin sheets 
Thus pain signals are primarily conducted to the brain by Aδ- and C-fibers. Figure 1 
shows the perceived pain following noxious stimulation, where the signals 
conducted by the faster Aδ-fibers will arrive first to the brain and will subsequently 
be felt as a sharp, pricking pain (termed “first pain”). This sensation is followed 
shortly after by the second pain, when the signals from the slower conducting C-
fibers arrive. Second pain is felt as a more diffuse and dull pain.  
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Figure 1: Pain following a stimulus is experienced first as a sharp pain (signals carried by 
the fast, myelinated Aδ-fibers) followed by a more dull and burning sensation (signals 
carried by slow, non-myelinated C-fibers). 
 
2.2. Spinal cord processing 
The primary afferents terminate in the dorsal horn where the signal is relayed to the 
secondary neurons. The dorsal horn is organized in layers (laminae I-VI). The Aδ- 
and C-fibers mostly terminate in the superficial layers (I-II), but some travel to the 
deeper layers. The information is relayed from the primary afferents via 
neurotransmitters, which can either inhibit or facilitate the neuronal activity25. 
Various neurotransmitters exist one such is glutamate which is important 
throughout the nervous system26.  
Once the nociceptive signal has entered the spinal cord, it is relayed via ascending 
pathways to the thalamus and the brainstem which in turn activates the higher 
cortical centers26.   
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2.3. Cerebral processing 
Once the nociceptive signal reaches the brain, an array of cortical centers are 
activated to process the signal. The exact areas involved depends on the noxious 
stimulus26. The most commonly activated centers include: the primary 
somatosensory cortex (S1), the secondary somatosensory cortex (S2), insula, 
anterior cingulate cortex and the prefrontal cortex27. These structures have been 
observed consistently across studies, and elicit responses which are correlated to the 
intensity of pain, and have therefore been named the “pain matrix” for its apparent 
participation in generating the perception of pain28–30. 
However, never studies have cast doubt on the concept of the pain matrix as solely 
responsible for generating the perception of pain from nociception, by 
demonstrating that the activity in the pain matrix also was modulated by the 
saliency of the noxious stimulus rather than the perceived pain intensity as well as 
the stimulus intensity31. This indicates that even though the cortical centers 
represented in the pain matrix are activated by painful stimuli, their response is not 
specific to the perception of pain and stimulus saliency seem just as dominant for 
the brains response19.  
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Chapter 3. Pain treatment 
Pain decreases quality of life significantly for patients, and is a common reason for 
patients to seek medical care5. The World Health Organization therefore devised a 
three-step ladder (see figure 2) for treatment of cancer pain, which has since been 
adopted for all pain treatments32,33. The ladder serves as a guideline for analgesic 
therapy with the goal to achieve successful pain control using the least potent 
analgesic first. 
 
Figure 2: The WHO three-step ladder for pain treatment to guide physicians when 
prescribing analgesic therapy 
According to the ladder, pain patients first presenting with pain should be treated 
with non-opioid analgesics. If the pain persists, a weak opioid such as tramadol can 
be added to treatment at the second step of the ladder. Should the weak opioids still 
be insufficient to achieve adequate pain relief, the last step of the ladder allows for 
substituting the weak opioid with a strong opioid such as the current golden 
standard in opioid therapy which is morphine34.  
Despite the existence of guidelines large differences exists in the agents prescribed 
as well as the quantity, putting into question how the guidelines are interpreted or to 
what extent they are followed32. Furthermore, doctors in Northern Europe are much 
more likely to prescribe opioids than in Southern Europe, with close to 0% of pain 
patients in Italy being on strong opioids such as morphine, while the figure for the 
United Kingdom was 12%5. This discrepancy in treatment approach probably 
contributes to the unsatisfactory pain control for around 40% of patients5  
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3.1. Opioids 
Opioids is a group of analgesic drugs which binds to the opioid receptors found 
throughout the nervous system35. More specifically, four receptor types exist; µ 
(mu), δ (delta) and κ (kappa) receptors as well as the opioid-like receptor 135. 
Opioids exert their effect on the receptors with either an agonistic or antagonistic 
effect. For example are both morphine and oxycodone thought to exert their 
analgesic effect by binding to the µ-receptor as an agonist, in CNS and to some 
degree in the peripheral nervous system36.  
Opioids exert large parts of their effect in the brain, and therefore the electrical 
activity recorded as EEG is affected37,38. However there is not complete agreement 
in the literature, as different methods for analysis complicate comparison of results 
and results on the EEG vary even for a single opioid39. The most common effect is a 
slowing of the EEG seen as an increase in the delta (1 – 4 Hz) band40–42. However, 
stronger opioids with higher receptor-affinity have been shown to affect the EEG in 
a more widespread way. Buprenorphine and fentanyl are both strong opioids with 
an affinity 25-10043 and 75-10036 times greater than morphine. These were studied 
to investigate the spectral EEG activity in response to painful electrical stimulation 
when administered through a transdermal patch44. Buprenorphine increased activity 
more, and in a more widespread frequency range than fentanyl (See figure 3), 
indicating a large difference in the EEG following treatment with the two opioids, 
despite being administered in equipotent doses. Therefore, impact on the EEG 
seems not defined by the opioid potency alone, but possibly by the receptors and 
mechanisms by which the opioids exerts their effect44. 
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Figure 3: Relative changes in frequency bands over time in evoked brain potentials following 
electrical stimulation of the median nerve (wrist) after administration of a) buprenorphine 
and b) fentanyl. Both doses were equipotent in terms of morphine equivalent units and 
delivered via a transdermal patch. 
 
3.2. Opioid responsiveness 
The opioid response is heterogeneous with large parts of the population not 
responding. For morphine around 30% of patients are not non-responsive to 
morphine treatment10. There is no difference between opioids in response rate, but 
there seem to be large variation for the individual as to what opioid provide a 
satisfactory analgesic effect34,45. Currently, opioid selection is done based on the 
doctors experience on a trial-and-error basis, where non-responding patients can be 
switched to another opioid if the first choice is ineffective46. This approach to 
treatment does not account for the individual patient and often leads to 
unsatisfactory results46, which is further reflected in 40% patients experiencing 
unsatisfactory pain management5. For example, one study raised the response rate 
from 74% to 96%, when patients not responding to morphine treatment was 
switched to another opioid14. This indicates that there is a large potential within 
pain treatment to select the right opioid for each individual patient15,18.  
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3.3. Personalized medicine 
Personalized medicine is the concept of using biomarkers to optimize medication 
type and dosage for the individual patient15. The concept of personalized medicine 
is explained in figure 4 together with the current method based on trial and error. 
Using the personalized medicine model it is more likely that patients will receive 
the right treatment initially and subsequently attain pain relief, as opposed to the 
current model where non-responders have to go through more treatments to achieve 
response. As a consequence suffering in these patients is prolonged, they 
experience more adverse effects and risks of development of chronic pain and drug 
abuse is increased.  
 
Figure 4: Schematic illustration of the current method for pain treatment and the principle 
behind personalized medicine. The current method has patients all treated with the same 
drug, of which some will respond and some will not. After it has been established that the 
non-responders are not properly treated they will be switched to an alternative analgesic to 
properly manage their pain. The personalized medicine approach will start out by classifying 
patients into different treatments depending on the appropriate drug of treatment, thus 
minimizing suffering and possible development of abuse. 
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The challenge with personalized pain medicine is to find reliable biomarkers for 
opioid responders and non-responders in order to identify potentially problematic 
patients. Several studies have attempted to identify simple parameters to distinguish 
between responders and non-responders using methods such as QST and different 
questionnaires such as pain catastrophizing, but results have been conflicting16,17. 
This indicates that there is still a need for additional parameters and/or new 
methods to combine parameters in order to achieve a reliable prediction of 
response16. Response to opioids is also affected by e.g., genetics, gender and age11–
13. Since pain is a perception generated in the brain19, differences in brain function 
could also reveal who will respond to different analgesics. EEG can assess 
individual changes in brain function and could therefore be a valuable tool for 
discovering biomarkers20. This study attempts to investigate if EEG can be used as 
a new biomarker for opioid analgesic response (Paper II and III). EEG is an 
objective method, which is also economically feasible and can be performed at 
bedside. The next chapter will explain EEG in further detail. 
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Chapter 4. Clinical parameters 
Clinical data is usually connected to a degree of variability since the condition of 
individual patients are always different. To assess these differences and whether the 
patient cohort is representative, clinical parameters are collected. Some clinical 
parameters are common in most studies, such as age, gender and body-mass index, 
while others are entirely specific to the condition of interest. Paper III focuses on 
patients undergoing total hip replacement surgery, and in this chapter the clinical 
parameters specific to this patient group will be briefly explained. 
4.1. Chronic Pain Assessments 
Two assessments of chronic pain were used in paper III; one assessment by the 
clinician and one by the patient. The chronic pain grade was developed for patients 
to assess the severity of their chronic pain both in terms of pain intensity and how 
limiting the pain was for everyday life47. Chronic pain was divided into four pain 
grades which briefly can be explained as: 
 Grade I:  low pain intensity, low disability 
 Grade II:  high pain intensity, low disability 
 Grade III: high disability – moderately limiting 
 Grade IV: high disability – severely limiting 
Patients who only experience low disability from their chronic pain belong in grade 
I and II as it is based on purely on pain intensity. Grade III and IV are based on the 
disability the patient is experiencing and is therefore only assessing how limiting 
the pain is47. 
The Mainz Pain Staging System (MPSS) was also used and is an assessment for 
clinicians for pain48,49. The clinician used the score to divide patients into three 
stages of pain chronicity. 
4.2. Passive Hip Rotation 
A simple test was developed to assess magnitude of evoked pain during passive 
rotation of the hip. The leg and knee was brought into a flexed position and rotated 
until the patient experienced pain. The leg was then brought into this position and 
held for 30 seconds. Then patients were asked to rate their overall pain on an 11-
point numerical rating scale (NRS). 
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4.3. Response score 
Since there is no validated definition for opioid response in a postoperative setting, 
we developed a “response score” in paper III to stratify patients into opioid 
responders and non-responders. The response score was determined based on the 
“Quality Improvement in Postoperative Pain Management” Questionnaire (QUIPS). 
QUIPS is a validated outcome measurement for postoperative quality control. A 
point-based response score was developed in order to stratify patients into opioid 
responders and non-responders. Points could be awarded up to a maximum of 10, 
and questions and instructions for awarding points can be found in Table 1. Cut-offs 
were based on typical intervention thresholds for postoperative pain management 
(e.g. pain on movement or maximal pain of 5)50,51. Patients with a response score of 
5 or greater were considered opioid responders, a score of 4 or lower would indicate 
a non-responder. 
 
Table 1: Explanation of the questions in the response score, and how points are distributed 
depending on the answers given for each question. Some questions are rated on an 11-point 
numerical rating scale, while others are simple yes or no questions.  
Questionnaire entry Answer Points awarded 
Maximal pain 0 – 4 
5 - 10 
2 
0 
Pain on movement 0 – 4 
5 - 10 
2 
0 
Minimum pain 0 – 2 
3 - 10 
2 
0 
Pain on mobilization Yes 
No 
1 
0 
Pain when coughing Yes 
No 
1 
0 
Pain when waking up Yes 
No 
1 
0 
Pain affecting mood Yes 
No 
1 
0 
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Chapter 5. Quantitative Sensory 
Testing 
Clinical pain are often associated with other factors such as anxiety, cognitive and 
autonomic responses and fear52. Perception of pain is also influenced by gender and 
cultural background making evaluation difficult53. QST uses experimental pain 
models to assess the pain system by invoking pain under controlled circumstances 
and are advantageous since they can eliminate many of the aforementioned 
problems to some degree dependent on experimental setup54,55. QST models consist 
of a stimulus which is assessed with subjective methods such as a NRS or by 
objective measurements such as EEG55. The information which can be derived from 
the QST tests are largely dependent on the evoking stimulus, of which a large 
selection is available55. This chapter will describe the QST models utilized within 
papers I, II and III. 
 
5.1. Cold Pain 
Cold stimulations are carried to the brain primarily by the Aδ- (cold sensation) and 
C-fibers (cold pain)56. The most common modality for cold pain stimulation is the 
cold pressor test, which is also used in papers I, II and III. The test is performed by 
submerging the hand in cold water (temperature range 1 – 7 ˚C) and maintaining it 
there for a specified amount of time (e.g. two minutes)57. Patient will then rate their 
overall pain on a NRS or another pain rating scale, or in some cases rating will be 
continuous during the stimulation such as in paper I. The stimulation constitutes a 
tonic stimuli which has been shown to better mimic clinical pain due to the length 
of stimulus and the intense unpleasantness felt during stimulation58. Furthermore, 
tonic cold pain stimulation has been shown to be rather sensitive towards detecting 
opioid analgesia55. However, the cold pressor test has been shown to be somewhat 
variable depending on the individual and experimental methods59. The introduction 
of new specialized equipment for maintaining water temperature and circulation in 
the water is thought to mitigate some of this variability57, but some inter-individual 
variability is still present.  
Papers I and II used cold pain stimulation for determination of opioid response, 
since it sensitive to opioid analgesia55. Papers I, II and III included the method as a 
QST measure and recorded EEG during the evoked pain. Papers I and II used 
specialized temperature-controlled equipment with continuous circulation of the 
water. However, this equipment was not available for paper III which used a 
thermal container with cold water inside for the test. To ensure a consistent 
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temperature of the water was used, temperature was measured before pain 
stimulation each time. 
 
5.2. Pressure Pain 
Pressure can induce pain in the skin by use of pressure algometry60. This painful 
sensation is mediated to the brain through Aδ- and C-fibers60. An algometer is 
usually operated by the examiner, who increase pressure at a constant rate until the 
patient indicates that their pain threshold has been reached and the pressure required 
is the quantifiable pressure pain threshold or predefined suprathreshold levels. 
However, it can be difficult to increase the rate at a constant pace, and it is therefore 
recommended that the same examiner always perform the test in order to reduce 
variability61. Paper III included the pressure pain in order to assess the pain system 
of patients preoperatively. 
 
5.3. Heat Pain 
Heat pain is another kind of thermal stimulation which is also mediated by Aδ- and 
C-fibers. Heat can be applied both rapidly and slowly, depending on which kind of 
stimulation is of interest. Rapid stimulation will quickly activate Aδ-fibers which 
will mediate the sharp feeling of “first pain” within less than 0.5 seconds. “Second 
pain” is felt slower as it is mediated by the C-fibers. As such, the fibers that are 
activated can to some degree be controlled with the rate of temperature increase55. 
Paper III included slowly increasing (1˚C/s) heat pain stimulation as a QST measure 
to assess the preoperative state of the pain system in order to activate both Aδ- and 
C-fibers. 
 
5.4. Conditioned Pain Modulation 
Pain is modulated by inhibitory and facilitatory mechanisms which are influenced 
by a number of factors. Conditioned pain modulation (CPM) represents the 
relationship between the descending inhibition and facilitation. CPM is assessed by 
application of a conditioning noxious stimulus which will inhibit the pain induced 
by another test stimulus. CPM can be performed using a wide range of conditioning 
stimulation modalities62, most common among them is the cold pressor test63.  
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In paper III the CPM effect was measured since it has been shown to be decreased 
in patients with experimental and clinical pain64–66. CPM was assessed using the 
cold pressor test as a conditioning stimulus, and the slowly increasing heat 
stimulation as a test stimulus. 
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Chapter 6. Electroencephalography 
EEG records the summation of electrical activity of the brain which is generated by 
the simultaneous firing of neurons and is well-known within pain and 
pharmacology research27. EEG can be recorded both locally (as local field 
potentials), on the surface of the cortex or on the surface of the scalp67. Due to the 
invasive nature of the first two methods, surface EEG is most commonly used as it 
is more clinically feasible to record and is therefore also chosen for this PhD 
thesis67,68.  
The primary advantage of EEG is the high temporal resolution and hence EEG 
allows for analysis of sequential brain activation, frequency information and 
direction of information flow due to pain or analgesics. The major disadvantage of 
surface EEG is the relatively poor spatial resolution due to all measurements being 
made at the scalp surface as brain signals recorded on the scalp are distorted due to 
volume conduction. Compared to imaging methods, the poor spatial resolution 
limits the ability of EEG in pinpointing the exact brain centers involved. On the 
other hand, the temporal resolution of imaging solutions is very poor (on second 
time-scale) and thus it is impossible to study sequential brain activity and ultimately 
separate pain specific from nonspecific activity as the pain stimulus reaches the 
brain within milliseconds of being presented. Furthermore, the costs and logistics 
involved in imaging solutions are severe limitations, making EEG a more suitable 
choice for developing a clinical bed-side system for prediction of opioid analgesic 
effect69.  
 
6.1. Generation of the EEG 
The main contributor of the surface EEG is the summation of excitatory and 
inhibitory neurons in larger populations of neurons, which transmit to the surface 
via volume conduction68. The signal decays over distance, and therefore the largest 
potentials measured at the scalp surface is generated by the cortex, although deeper 
sources can also be identified67,68  Since the generated electric field for the 
individual neuron is small, both the structure in which neurons are organized67 as 
well as the synchronization of neuron firing is of great importance in order to 
generate a measurable potential at the scalp surface39,67. In the cortex, neurons are 
arranged perpendicular to the surface of the cortex, forming layers of neurons in 
palisade67. Activation can occur in synchrony and within defined layers, enabling 
generation of quite large potentials67. 
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EEG can be recorded in two main categories: spontaneous EEG such as during rest 
or a prolonged stimulus and event-related potentials which are the direct response 
to a phasic and external stimulus68. This PhD thesis focuses on the spontaneous 
EEG during rest and cold pain. 
6.2. Recording Surface EEG 
Surface EEG has amplitudes in the order of microvolts (μV) and therefore needs to 
be amplified in order to be accurately measured67. Since the potentials are 
miniscale, differential amplification between two electrodes (an active electrode 
and the reference electrode) is necessary. This amplifies the difference in voltage 
between the two electrodes and has the advantage of cancelling out common signals 
between electrodes67.  
The frequency bandwidth of interest for EEG signals ranges from around 0.1 -100 
Hz67. Filtering is often necessary due to noise such as: 
 Slow voltage drift (slowly changing voltages). 
 Muscle artifacts. 
 Mains noise (50 or 60 Hz depending on country). 
 Artifact from cables and other sources, 
The voltage drift noise is caused by slowly changing properties of the electrode gel, 
electrodes or skin resistance67. These signals can be removed using a high-pass 
filter with a cut-off frequency of around 0.1 – 1 Hz67. Papers I, II and III all used 1 
Hz as the cut-off frequency. 
Muscle artifacts are generally high-frequency signals outside the frequency 
spectrum of the EEG, and is commonly removed using a low-pass filter set as low 
as possible depending on the spectrum of interest67. 30 Hz is a common cut-off, or 
70/80 Hz if the gamma band is of interest. Papers I and II used 70 Hz as a cut-off 
while paper III used 32 Hz since the gamma band was excluded. 
Mains noise can arise from the electrical net if the desired spectrum arises above 50 
or 60 Hz (i.e. if the gamma band is of interest)67. To combat this problem a notch 
filter at the specified frequency is utilized. Since papers I and II included the 
gamma band, a notch filter designed for 50 Hz was employed. 
Electrodes can be contaminated with noise which cannot be removed with filters. 
Signals from such electrodes are then rejected and an average signal is interpolated 
from neighboring electrodes to replace it. This is done manually and to preserve 
integrity of the recording it is essential that a limited number of channels is 
interpolated. If too many channels are affected by noise the recording will have to 
be rejected.  
Since there are activity differences between brain structures, it is often desirable to 
record EEG from multiple locations spread over the scalp, to give a full 
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representation of the neuronal activity67,68. These electrodes are placed according to 
the 10-20 system which is universally accepted67. Number of electrodes can vary 
widely (up to 512 electrodes or more) depending on the application. A high number 
of electrodes is desirable for full representation of neuronal activity. However, as 
the number of electrodes increases more time is required for mounting, problems 
with high impedance between scalp and electrode increases and general expense of 
the system is also increased. Therefore a trade-off in the number of electrodes is 
required and depends entirely on the application. Papers I and II used a 62-electrode 
recording cap, as the study was experimental and included relatively few subjects. 
Paper III was a clinical study and therefore a 34-electrode cap was used to decrease 
mounting times. A clinical algorithm for personalized pain medicine will likely 
need to reduce this number even further, when the electrodes of interest have been 
established. 
 
6.3. Evoked Brain Potentials 
Evoked brain potentials is the time-locked response to an external stimulus 39,68. 
Since the response to is highly dependent on the sequential activation of various 
brain centers, the evoked brain potentials have a specific morphology, as can be 
observed in figure 5 as the average potential39. In order to obtain the time-locked 
properties of the evoked brain potentials it is necessary for the evoking stimulus to 
be short and rise rapidly in intensity67. The potential is characterized by negative 
and positive peaks which is commonly quantified by their peaks (estimates amount 
of synchronously activated neurons) and latency (estimates delay conduction from 
the periphery and in activation caused by delayed cortico-cortical connections)39. 
The most common peaks are described in Table 2. 
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Table 2: The different peaks of evoked brain potentials, their latency and from which areas 
of the brain they originate. 
Peaks Latency [ms] Typical brain area General interpretation 
Early70  20 - 60 Primary somato-
sensory cortex 
Non-pain specific 
somatosensory input from 
touch. 
Intermediary40  60 – 120 
 
Operculum 
Limbic system 
Reflects nociceptive 
activation of supraspinal 
structures. 
Late71 120 - 350 Operculum 
Limbic system 
Reflects discomfort or 
Emotional aspects of 
pain. 
 
Due to low signal-to-noise ratio of recorded evoked brain potentials, stimulation is 
normally repeated a number of times while recording the EEG and subsequently 
averaging all trials to get the average response to the stimuli72. When the technique 
was first developed EEG would often suffer from poor signal to noise ratio. 
Although much has been improved since in the recording techniques, post-
processing and filtering, the averaging method is still widely used since the 
averaging procedure makes the evoked potential stand out from the background 
EEG in the signal44. However, there are many drawbacks to averaging, since it only 
preserves components which are time-locked to the stimulus73. Since this is not the 
case for all nociceptive input, averaging effectively removes useful information 
from the signal along with noise73. The reduction in variability by use of averaging 
is shown in figure 5. Use of more advanced time-frequency analysis on each EEG 
signal from each repeated stimulation (termed single-sweep analysis) has been 
shown to increase reliability74, sensitivity to analgesics44 and neuronal changes due 
to disease75. 
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Figure 5: Single-sweep evoked brain potentials (green) and the resulting average potential 
(black). The loss of variation from the underlying single-sweeps by applying the averaging 
procedure is apparent. 
The emergence of fast and affordable computing has enabled analysis of each 
individual trial, also termed single-sweep analysis. This analyses the signal 
including non-time locked components, and has been shown to be superior in 
detecting the effect of analgesic drugs44, and in detecting differences in cerebral 
activity in patients with fecal incontinence75. 
 
6.4. Continuous EEG 
Continuous EEG is not time-locked to a specific stimulus like evoked brain 
potentials. It is rather a recording of EEG over a specified time period. Continuous 
EEG lacks the easily discernible peaks of evoked brain potentials and as such it is 
usually divided into frequency bands to describe different processes in the brain. 
The exact limits of the frequency bands differ, but they are roughly defined as: 
 Delta (δ): 1 – 4 Hz 
 Theta (θ): 4 – 8 Hz 
 Alpha (α): 8 – 12 Hz 
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 Beta (β): 12 – 32 Hz 
 Gamma (γ): 32 – 80 Hz 
Figure 6 illustrates an EEG signal and the division of the signal into frequency 
bands. 
 
 
Figure 6: Illustration of how the spectrum of the EEG signal can be divided into the 
predefined frequency bands; delta (1 – 4 Hz), theta (4 – 8 Hz), alpha (8 – 12 Hz), beta (12 – 
32 Hz) and gamma (32 – 80 Hz). 
Continuous EEG is susceptible to artifacts from eye blinking, eye movements and 
muscle artifacts, which occur at amplitudes more than ten times that of the EEG 
signal76. Therefore, various methods have been developed to remove these artifacts 
using independent component analysis which can separate the signal into 
components that appear to be independent76.  
 
6.4.1. Resting state EEG 
The most common recording of continuous EEG is made with the subject in a 
resting state. In this state subjects are instructed to be calm while either lying or 
sitting with little or no verbal communication. Resting EEG has been used 
extensively in combination with pharmacological agents to detect differences in the 
cortical activity following drug administration39. 
Resting EEG has a certain variability over time. To account for this variability it is 
recommended to used recordings of at least 120 seconds to get a steady recording77. 
Resting EEG has also been shown to drift gradually over time possibly due to shifts 
in attention state78,79. To maintain a constant attention level, special protocols have 
been developed to maintain vigilance, for example through simple arithmetic 
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tasks80,81. However, it has not been investigated if a similar drift occurs during these 
vigilance-controlled conditions. 
 
6.4.2. Tonic Pain EEG 
Tonic pain EEG is a variation of continuous EEG where the subject is undergoing a 
painful tonic stimulation. Tonic pain is thought to be a more physiologically 
meaningful stimulation that better mimics the perception of chronic pain due to the 
unpleasantness and time available for the brain to adopt to the painful event58. 
Furthermore, tonic pain models such as the cold pressor test are more sensitive to 
opioid analgesia possibly due to the deep pain evoked by the stimulation and higher 
level of unpleasantness55. Feeling of unpleasantness is connected to the limbic 
network which is an area where opioids are known to modulate pain response27.  
Thermal pain is a common tonic pain model, both heat82,83 and cold79,84,85 have been 
extensively used. Therefore, papers I, II and III employed the cold pressor test as a 
tonic pain stimulus. Tonic ischemic pain can also be induced by limiting the blood 
supply by use of a blood pressure cuff and has been used in clinical studies86 and in 
combination with EEG before87. In addition, the relationship between ischemic pain 
and time is largely linear as opposed to the cold pressor test which experiences a 
ceiling effect58. 
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Chapter 7. Feature extraction 
EEG signals consist of millions of data points which in itself is impractical to 
assess. Feature extraction is the process of extracting overall characteristics from 
the many data points, in order to describe the signal with fewer numbers. A myriad 
of feature extraction methods exist, such as spectral analysis, mean dominant 
frequency, 95% spectral edge, sample entropy and connectivity81,88–91. For this 
thesis spectral analysis was used since it is well tested and has been proven useful 
in many studies. Also it does not discard any part of the spectrum and should 
therefore provide a more complete assessment of the signal.  
 
7.1. Spectral analysis 
Spectral analysis investigates the energy of the signal within the standard frequency 
bands. The Fourier transform has for many years been the golden standard for 
frequency analysis within EEG since the first introduction in 193292 although the 
method has several limitations93. Fourier analysis requires relatively long signal 
segments for detailed frequency resolution, and makes assumptions about the signal 
stationarity which is not fulfilled for EEG data94,95. Even so it is a commonly used 
method, and the variability of EEG measures derived using the Fourier transform is 
heavily dependent on the recording length96. Thus, longer recordings are more 
robust, and commonly a recording length of at least 20 seconds have been 
recommended97. However, newer evidence suggests that much longer recording 
lengths of at least 120 seconds should be used in clinical and pharmacological 
studies, to reduce influence from noise96. Several other methods exist for spectral 
analysis, the most common are listed in Table 3.  
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Table 3: Overview of common time-frequency algorithms for analysis 
Name Description Advantages Drawbacks 
Fourier 
transform98 
Classic frequency 
analysis.  
Low computational 
cost 
Time-frequency 
resolution 
Wigner-Ville 
distribution99 
Simple instance 
of Cohen’s class 
High temporal 
resolution. 
Well-suited for 
non-stationary 
signals such as 
EEG 
Influenced by 
cross-term 
interference. 
Density estimate 
can result in 
negative values. 
Matching 
pursuit100–102 
Uses a redundant 
dictionary of 
atoms for 
decomposing the 
signal into a 
sparse 
representation  
Time-frequency 
resolution adapted 
to the signal 
Does not 
represent all 
frequencies, 
making 
comparisons to 
other studies 
difficult. 
Computationally 
costly 
Wavelet 
analysis103,104 
Multi-resolution 
analysis. Higher 
temporal 
resolution for 
high frequencies 
and higher 
spectral 
resolution for 
low frequencies 
EEG signals have 
properties suitable 
for multi-resolution 
analysis. 
Requires a 
mother wavelet 
function, which is 
an a priori 
assumption that 
can affect 
outcome 
 
 
An alternative is the wavelet transform which takes a different approach to spectral 
analysis, by decomposing the signal into coefficients through use of a mother 
wavelet function103. Mother wavelet functions can be selected from a library or 
developed independently to satisfy the mother wavelet criteria; zero mean value, 
finite energy and relatively little low frequency content compared to high frequency 
content95. During analysis the mother wavelet is scaled, changing its center 
frequency and thus achieving affinity for different frequencies. The process also 
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illustrated in figure 7 is repeated for scales matching the frequency range of 
interest103.  
 
Figure 7: Decomposition of a signal using a mother wavelet function at different scales. The 
mother wavelet is scaled to a certain length, and compared to the signal, moving the wavelet 
along the signal to result in a continuous comparison. The mother wavelet is then scaled 
again and the process is repeated until all desired scales have been used.  
The wavelet coefficients are then used to establish the frequency content within 
each band. Two variants exist to measure the content; power and amplitude. The 
only difference being that the amplitude uses the absolute of the wavelet 
coefficients, while the power uses the square of the absolute values. The two 
measures are more or less equivalent, however power tends to put over-emphasis on 
short-high amplitude bursts which is characteristic for eye movement artifacts and 
other sources of noise. For this reason, the amplitude was chosen as the measure of 
frequency content for this thesis (Papers I, II and III).  
The average frequency content within each frequency band is calculated, and the 
values are termed as the absolute EEG indices. However, due to the high inter-
individual variability introduced due to factors such as scalp thickness, electrode-
gel conductance etc., the relative EEG indices have also been utilized as a feature in 
EEG research105. Relative indices are expressed as the percentual contribution of 
each band to the total EEG amplitude, calculated by dividing each absolute EEG 
index by the sum of all absolute indices. Relative EEG indices accounts for more 
inter-individual differences and is shown to show a higher correlation with brain 
perfusion as measured using positron emission topography106. However, relative 
EEG indices suffer from interactions between frequency bands since it is a relative 
measure. Thus, if one frequency band increases in amplitude, other frequency bands 
must decrease accordingly. This can complicate studies which compare conditions, 
such as drug studies and many pain studies. When several frequency bands are 
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changing at the same time, this can make an increase in a frequency band appear as 
a decrease simply because the other bands are counterbalancing these changes79. 
Both measures provide complimentary information, and neither is more correct than 
the other106,107. The measures are best used in unison, where full advantage can be 
taken of the information (Paper I). This is especially true for studies which compare 
EEG under different conditions for the same subject. Paper II and III only used the 
relative spectral content since it is less susceptible to inter-individual differences. 
 
7.2. Functional connectivity 
Another way to assess EEG is through functional connectivity which has been used 
extensively with structural and functional magnetic resonance imaging108,109. The 
common spectral analysis will assess EEG amplitude in different frequency bands, 
and is as such a measure of brain rhythmicity110. Functional connectivity tries to 
assess the flow of information between electrodes by considering the brain as a 
complex network of inter-connected nodes (electrodes)108. Many different methods 
exist for assessing functional connectivity, but most rely on the phase differences 
between electrodes to assess which electrodes are communicating and which 
direction information is flowing as exemplified on figure 8111,112. This is typically 
achieved by calculating the phase-relationships between signals. Electrodes with 
similar phase-relationships are considered to be exchanging information111–113. 
The methods have been used to show decreased cortical connectivity after 
remifentanil110, distinguishing between levels of consciousness in comatose 
patients114 and detection of decreased information flow in diabetes patients115. 
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Figure 8: Illustration the principle behind functional connectivity. The signal from the 
receiving electrode (blue) is phase-shifted compared to the signal from the driving electrode 
(red). This indicates a strong connection between the two electrodes. The driving and 
receiving electrode can be distinguished by which signal occurs earlier if directionality is 
investigated.    
This PhD thesis included functional connectivity in paper III to attempt assessment 
using a slightly more advanced parameter. The phase-lag index (PLI) is quite 
resistant to volume conduction since it discards most phase-relations between 
electrodes with no differences in phase (likely caused by volume conduction) and 
was therefore chosen for analysis111. Furthermore, PLI has already been shown to 
be reliable108. 
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Chapter 8. Machine learning 
Machine learning derives from pattern recognition and is a common term for 
methods which learn from and make predictions based on learning data. Machine 
learning methods work by constructing a model based on a set of training data 
belonging to two or more discrete groups, which can subsequently be used for 
predicting outcomes for future samples. It enables simultaneous assessment of 
multiple variables on an individualized basis. This is in contrast to conventional 
statistical methods, which often analyze single variables between groups of patients 
and rely on a priori assumptions. 
Within machine learning there are three main branches of methods; supervised, 
non-supervised and reinforced learning;  
 Supervised learning methods require information regarding the groups in 
order to construct a model optimized for a specific problem. Suitable for 
problems where a general rule is needed to determine an outcome based on 
a given data sample 
 Non-supervised learning does not require any information regarding which 
samples belong to each group. Non-supervised learning will instead try to 
find structure in the training data and is thus able to find hidden patterns in 
data. 
 Reinforced learning takes place when the model must perform a certain 
task and repeatedly learn to do the task better based on feedback it 
receives. An example of this could be a computer learning to play a 
computer game against an opponent. 
Since the object of this project is to differentiate between two pre-defined groups, 
supervised learning was chosen as the appropriate method. Several different 
methods exist within supervised learning, among others; linear discriminant 
analysis, artificial neural networks, support vector machine and Bayesian 
classifiers.  
8.1. Feature selection 
Until little more than a decade ago, few areas of research investigated more than 40 
features116. This has changed dramatically in recent years, where some studies 
investigate numbers of features in the range of tens of thousands117. Now all 
possibly relevant features are collected and subsequently subjected to a statistical 
feature selection process to establish which features are relevant to the classification 
problem. Feature selection is the process of selecting a subset of relevant features 
from a larger pool of variables. This is done for several reasons, among others; 
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 Making results easier to interpret 
 Decrease training time for the machine learning models 
 Increasing generalization by reducing over-fitting 
The main goal of feature selection is to identify and remove features which are 
either redundant or irrelevant as they can be removed without significant loss of 
information118. 
Feature selection methods can be either wrappers or filters117. Wrappers are 
specific to the chosen machine learning classifier and work by searching through all 
features using the accuracy of this classifier. This however can be very expensive 
computationally (especially with large numbers of features), and might result in 
solutions which are overly specific to the classifier117. Filter methods work 
independently of the classifier and instead define a measure of relevance to 
approximate the value of a feature within the current classification problem117. This 
makes feature selection possible using only few assumptions. Filter methods are 
relatively computationally inexpensive while generally being less susceptible to 
over-fitting than wrappers117. As such filter methods were chosen as the feature 
selection approach for this study. 
Filter methods are all defined primarily by their measure of relevance which tries to 
describe the utility of including a given feature in the reduced feature set 117. 
However, there are countless ways to define relevance, and as a result a large array 
of different feature selection methods exist117. The question then becomes which 
method to choose over the other available methods. A recent study reviewed 17 
methods for feature selection under three criteria117: 
 Inclusion of a conditional redundancy term 
 Balancing the relevance and redundancy terms 
 Use of low dimensional approximation, important for small sample sizes 
Only three out of 17 methods were found to fulfill all criteria; joint mutual 
information (JMI), mutual information maximization and conditional mutual 
information maximization117. JMI was recommended as giving the best tradeoff 
between accuracy and stability and thus was selected for this study119.  
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8.2. Support vector machine 
Support vector machines (SVM) were first introduced in 1963 by Vapnik and 
Lerner seeking a method to find the optimal (defined by the largest margin) 
hyperplane to separate two distinct classes of data120. The basic principle is 
explained in figure 9. Here it is illustrated that the data can be separated by a 
number of hyperplanes. However, to find the hyperplane with the largest margin, 
the SVM identifies points closest to the border (support vectors), and uses them in 
the calculation as shown in figure 9. 
 
Figure 9: Illustration of the basic working principle of the SVM to separate two classes of 
data. A) The classes can be separated by a number of hyperplanes. B) The hyperplane with 
the largest margin (arrow) is shown with the support vectors used to calculate it 
 
8.2.1. Soft margin SVM 
The first implementation of the SVM assumed that data would be perfectly 
separable120. However, real world data and especially human biometric data as used 
in this study is rarely perfectly separable and will include a certain amount of 
overlap between classes. To accommodate this, the soft-margin SVM was proposed 
which allowed for misclassifications and which has since been the most common 
implementation121. The soft-margin SVM assigns a penalty for misclassified 
samples. The optimization of the hyperplane then becomes a compromise between a 
large margin and a small error penalty. The cost variable C was introduced to 
control the tradeoff between margin and error penalty and also serves as a 
regularization parameter for the SVM, which can be adjusted to increase 
generalization of the classifier122. This type of classifier has now widely replaced 
the original classifier, and is also used in papers I, II and III. 
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8.2.2. Kernel functions 
The original SVM was developed as a linear classifier120. However, not all real-life 
problems will present with data that is linearly separable. To allow for non-linear 
classification, kernels were introduced123. This is an interesting implementation 
because the hyperplane is still linear, but instead the data is transformed into a high-
dimensional feature-space where a linear hyperplane can separate the data, even 
though the separation might be non-linear in the original feature-space123. Figure 10 
shows how the transformation into a different features space can make a non-
linearly separable dataset become linearly separable.  
 
Figure 10: Transformation of a feature-set into a different feature space enables linear 
separation using a support vector machine. A) The features in the normal feature-space, 
where the decision boundary appears non-linear. B) The features in the transformed feature-
space where the decision boundary is linear. 
However, kernel functions can present with the problem of over-fitting and 
subsequent loss of generalization124. This is unfortunate since the results of the 
SVM are pointless unless the results are generalizable to the general population. 
The problem is demonstrated in figure 11, where an overly complicated decision 
hyperplane makes the performance poor when new data is introduced. For this 
reason it is recommended to use caution when using non-linear kernels to avoid 
over-fitting, as many times the generalization becomes inferior compared to SVMs 
with linear kernels124. Therefore, this project utilized a linear kernel to avoid over-
fitting (Paper II and III). 
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Figure 11: Over-fitting of the support vector machine using an overly complicated decision 
rule which will provide poor generalization and sub-optimal results when applied to new 
data. 
8.2.3. Cross-validation 
The idea behind machine learning is to train a model based on a set of training data 
which can then correctly classify new samples of the same type. This poses 
challenges for studies trying to validate a classifier when the number of samples is 
limited. Firstly, the classifier’s ability to generalize new data also depends on the 
number of samples available for training, meaning that as many samples as possible 
should be included for training. Secondly, samples included for training cannot be 
used simultaneously for validating the classifier, as this can result in over-fitting to 
the data and subsequent poor ability to generalize to new data. The optimal solution 
is to build the model using training data from one study, and subsequently testing 
the model using completely separate data. However, this poses requires high 
numbers of samples which is not always possible or ethical to include in clinical 
studies.  
Cross-validation attempts to handle this problem by dividing the data into training 
and test subsets which can be validated without possibility for over-fitting. This is 
repeated multiple times with different training and test subsets, and the accuracy of 
the classifier is finally calculated as the average accuracy for all iterations125. This 
has the advantage of maximizing the number of samples that can be used for both 
training and testing. Several types of cross-validation exist, most common among 
them are: 
 Chapter 8. Machine learning  
 
47 
Leave-one-out: This type of cross-validation uses a single sample for testing, while 
the rest of the dataset is left for training. This has the advantage of maximizing the 
amount of samples for training in each iteration while still using all samples for 
testing in one iteration. This makes it well suited for small datasets, where the 
number of training samples is crucial. Furthermore, the method is exhaustive, 
meaning that all possible combinations of training and datasets are included and 
thus the result will always be the same. However, the method requires additional 
computer processing power due to the high number of iterations when using this 
method. 
K-fold cross-validation: This version of cross-validation divides the data into k 
equally-sized subsets. Each iteration is then made by using one subset for testing 
while the other subsets are used for training the classifier. A common value for k is 
10, but it can be set to any value of 2 or above. When 𝑘 = 𝑁, it is equivalent to the 
leave-one-out method. K-fold cross-validation generally uses less computing power 
due to the less number of classifications (if 𝑘 < 𝑁), but is also non-exhaustive, 
meaning that results will differ depending on how the data is split. 
Since the number of samples in this study was limited and the amount of computer 
processing power was not, leave-one-out cross-validation was chosen as the 
preferred method to avoid over-fitting (Paper II and III).  
 
8.2.4. Dealing with imbalanced datasets 
Part of the calculation for the soft-margin SVM (current golden standard) is to 
assign a penalty for incorrectly classified samples121. However, when datasets are 
overlapping significantly and group sizes are uneven it can result in inaccurate 
results126–128. More specifically, the classifier will become biased towards the 
majority class. This phenomenon is caused by the sheer number of overlapping 
samples from the majority class and will cause a greater penalty for the decision 
rule than the penalty for most or all of the samples from the minority class. In this 
case it is more optimal (incurring less penalty) for the classifier to simply classify 
all or most samples as belonging to the majority class128. This will result in higher 
accuracies than a classifier which will pay equal attention to both classes, but the 
heightened accuracy is essentially meaningless for prediction. The problem with 
imbalanced datasets is quite common within genetic profiling and medical 
diagnosis126 and usually it is the few samples minority class which holds the 
greatest importance for correct classification129. Figure 12 illustrates the problem 
for two classes with skewed group sizes. A typical SVM would strive for the 
solution shown in figure 12A because it yields fewer overall misclassified samples. 
However, the classifier would simply classify all samples as belonging to the same 
class, making the solution useless. A solution more similar to the one shown in 
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figure 12B would be more desirable since it correctly classifies the minority class, 
despite the lower overall accuracy. 
 
Figure 12: Skewed group sizes in overlapping data can have adverse effects on a machine 
learning classifiers ability to properly separate data. A) The more useful classification, 
which will have a lower overall accuracy due to the large number of misclassified samples in 
the majority class. B) The optimal solution for minimizing misclassified samples, but useless 
in practical terms since it always returns the same result. 
This problem, which is universal in machine learning, and not just restricted to 
support vector machines, has been addressed in two different ways: 
1. Balancing the original dataset 
2. Adapting the classifier to the dataset 
Balancing the dataset involves either under-sampling the majority class or 
oversampling the minority class until the classes are balanced126,128. Both methods 
have drawbacks, under-sampling being reported to perform sub-optimally126 for the 
SVM, but in other cases reported as performing successfully when combined with 
specialized data elimination techniques128. Although it must be noted that 
information is removed using this method. Over-sampling on contrary does not 
remove information, but has instead been reported to shift bias towards the minority 
class128. 
Adapting the classifier completely depends on the classifier but is most commonly 
accomplished by assigning different costs for misclassifying the different 
samples127,128. Studies show that SVMs in particular have the ability to deal with 
imbalanced dataset without introducing noise, however there is a chance for the 
resulting classifier to over-fit the data128. This was implemented in paper III due to 
the slight imbalance in group sizes. 
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Chapter 9. Results 
The key results from the paper I, II and III are found in this chapter. More detailed 
results can be found in the papers. 
9.1. Key results Study I 
 Recording of EEG (62 electrodes) during rest and cold pain was performed 
on healthy volunteers (N = 39) on two separate days and reliability 
between days were investigated. 
 Spectral indices of EEG during cold pain and resting is reliable with 
coefficients of variation at 10% or below. 
 Tonic cold pain induces widespread changes in the EEG over all frequency 
bands. 
 The EEG activity in the theta, beta3 and gamma bands were correlated to 
the average pain intensity. 
 Analysis of the EEG dynamics revealed that only theta was dynamically 
reflecting the pain response and therefore the more directly related to the 
perceived pain. 
 
9.2. Key results Study II 
 Healthy volunteers (N = 39) were included in a placebo-controlled 
morphine study. 
 EEG was recorded (62 channels) during rest and cold pain before and 60 
minutes after morphine administration where analgesic response was 
determined based on the reduction in pain ratings during cold pain. 
 Tonic painful EEG combined with support vector machine classification 
enabled reliable classification of opioid responders at a rate of 72% in 
healthy volunteers. 
 Conventional statistical methods could not differentiate between 
responders and non-responders. 
 Resting state EEG did not provide equally high classification accuracy.  
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9.3. Key results study III 
 Eighty-one patients undergoing total hip replacement surgery completed a 
clinical observational study. 
 Prior to surgery QST (heat, pressure pain), clinical parameters and EEG 
during rest and cold pain was recorded. 
 Patients were stratified into responders (N = 51) and non-responders (N = 
30) to oxycodone and piritramide based on their pain ratings the first 24 
hours after surgery. 
 Conventional analysis showed that there was connection between pre-
surgical pain state (chronic pain grade) and response to postoperative 
analgesic opioid treatment. 
 Support vector machine classification on tonic painful EEG predicted 
response to postoperative opioid pain treatment in 65% of cases in patients 
undergoing full hip replacement.   
 Resting EEG proved inferior to tonic painful EEG for prediction of 
analgesic effect.  
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Chapter 10. Discussion 
This PhD thesis investigated EEG as a biomarker for personalized pain medicine in 
the following steps: 
 To investigate reliability and dynamics of the EEG during rest and cold 
pain in healthy volunteers to assess robustness of the biomarker (Paper I). 
 Investigate if prediction of morphine analgesia is possible in healthy 
volunteers (Paper II). 
 Predict postoperative opioid analgesia in patients undergoing total hip 
replacement surgery (Paper III). 
The first part of the discussion focuses on the methodological considerations for the 
three studies while the rest focuses on the findings and challenges regarding EEG as 
a biomarker and the current state of the art within personalized medicine for opioid 
analgesia.  
 
10.1. Methodological considerations 
Papers I, II and III investigated the delta, theta alpha and beta frequency bands 
while the gamma band was only included in papers I and II. The delta band was 
shown to increase during tonic pain in paper I which is in line with earlier 
studies130. Furthermore, it was the primarily selected feature for classification in 
paper II as well as paper III, demonstrating the relevance of this low-frequency 
band. Alpha and beta were both also part of the classification in paper II and are 
both important for the perception of pain82,84,131 and opioids analgesic effects44. 
Furthermore, in paper I theta band activity seemed to be connected closer to 
perceived pain than any other frequency band.  
Recently, large parts of evoked brain potentials previously thought to be directly 
connected to the experience of pain has been shown instead to be closely related to 
the saliency of the stimulus31. However, newer and more advanced analyses have 
revealed features in the gamma band to be more specifically associated the 
perception of pain132,133. This makes the gamma band interesting for pain research 
and was therefore included in paper I to study the reliability of the frequency bands 
as well that the connection to tonic pain. However, even though the gamma band 
was shown to be reliable and the average gamma activity correlated to the pain 
rating the gamma band activity was not dynamic during the cold pressor test. Since 
the pain ratings during the cold pressor test are highly dynamic, it is unlikely the 
gamma band was directly reflecting the painful experience. This contrasts other 
findings, but could be due to the nature of the stimulus which in previous studies 
Personalized Pain Medicine 
52 
have focused on short, transient stimulations such as delivered by lasers compared 
to the tonic cold pain in paper I. When used for prediction in paper II, no gamma 
band features were selected for prediction of analgesic effect, indicating that the 
gamma band is of less importance for prediction of opioid analgesia. Due to the 
findings in papers I and II, and previous studies which suggest electromyographic 
artifacts are introduced into the EEG during the cold pressor test81, the gamma band 
was not included in paper III, so as to avoid influence from the gamma on other 
frequency bands (due to the relative spectral activity). 
Papers II and III attempted to predict opioid analgesia based on both resting EEG 
and EEG during tonic cold pain. Both studies showed that the EEG during cold pain 
was useful for prediction, while resting EEG was not. Paper I also revealed that 
resting EEG has slightly lower reliability than EEG during cold pain, possibly due 
to suppression of conscious and non-conscious processes during pain. Paper I 
additionally revealed unexpected drifting of the resting EEG during the 2 minute 
recording which could indicate drowsiness in the subject. Overall, it seems the 
painful stimuli bring out activity related to how the brain processes pain, which in 
turn is associated with the response to a given opioid. These findings indicate that 
EEG during pain is more suitable for prediction. However, only one stimulus (cold 
pain) was investigated so future studies could aim to investigate if other stimuli 
would yield better results.  
Papers I, II and III all utilized the cold pressor test for the evocation of tonic pain. 
The test was as standardized as possible, however some discrepancies in 
methodology still remained. The water temperature in paper I and II was controlled 
with a specialized equipment, keeping the temperature at 2˚C while constantly 
circulating the water. This type of equipment is preferable for cold pressor studies, 
where the temperature of the water and lack of circulation can reduce reliability of 
the pain model57. However, for paper III this equipment was not available on-site 
and instead relied on cold water from the tap in a thermal container. To account for 
the added uncertainties from this approach, temperature of the water was measured, 
and was found to be consistent between groups. The primary confounder due to the 
cold pressor equipment in paper III seems to be the temperature (around 8˚C) which 
is comparatively higher than the 2˚C used in papers I and II, but also the normal 
range of the cold pressor test (1˚C to 7˚C) 57. This also could contribute to explain 
why the overall accuracy in paper III was lower than in paper II. Comparison of 
resting EEG and EEG during cold pain revealed that the painful stimulation seemed 
to bring out the predictive features in the EEG. It therefore stands to reason that the 
lower stimulation intensity in paper III could fail to accentuate the predictive 
features sufficiently, thus resulting in a lower accuracy. This is supported by the 
comparison between resting EEG and EEG during cold pain revealed widespread 
differences in paper I, while the same differences were much lesser pronounced in 
paper III. This points to the need for an intense painful stimulus to properly 
individual differences in brain function related to opioid analgesic efficacy. 
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Paper II attempted to predict the analgesic effect of morphine on an experimental 
pain model (the cold pressor test) while paper III investigated the analgesia attained 
after total hip replacement surgery. Experimental pain models are advantageous 
since they are standardized with regards to the stimulus (nature, stimulation site, 
stimulus frequency and intensity)134. It also allows to exclude known confounding 
factors in clinical studies such as related symptoms, anxiety, immobility and pre-
existing medication55. Paper II therefore avoided these confounders, and found an 
algorithm which could predict morphine analgesia in 72% of cases, indicating that 
the EEG can be utilized for prediction. However, personalized medicine needs to be 
able to deal with the real-life confounders which might impede classification 
accuracy. Therefore, paper III investigated patients undergoing total hip 
replacement surgery in order to predict their post-operative analgesics response 
using pre-operative EEG. The clinical aspect introduced several confounders into 
the study, firstly patients were already suffering from chronic pain which can affect 
the EEG135,136. Additionally, the patients were already using medication to treat 
their pain condition, which also has a known effect on the EEG39. Lastly, there is a 
source of variability introduced by the surgery in itself. Though all patients 
underwent the same surgical procedure, variations in complexity and duration of 
surgery will always vary, which could affect pain post-operatively. All these factors 
likely contribute to the relatively lower classification accuracy in paper III. More 
knowledge is needed about the confounders and their interaction with the EEG in 
relation to features which might predict analgesic efficacy. As more studies emerge 
on the subject, new algorithms will be able to account for these confounders in a 
more satisfying way. 
Papers I and II analyzed the EEG by investigating the spectral content in predefined 
frequency bands. Paper III also included functional connectivity in the analysis to 
assess the communication between electrodes. Functional connectivity is a rapidly 
expanding field within EEG research, and is being heralded as the next step in 
analysis methods as it investigates the interactions between functional networks in 
the EEG activity109. More detailed information can be extracted by extending 
analysis from simple rhythmicity of individual electrodes to assessment of the flow 
of information between electrodes as well as direction111. Despite this, the feature 
reduction method did not result in selection of features from the functional 
connectivity features, but instead only selected a single feature from the spectral 
indices. Thus inclusion of these more advances features did not end up improving 
classification accuracy in paper III. Still, future studies should continue to 
investigate this method as it has proved promising in many studies110,115,137. 
Furthermore, functional connectivity parameters can be analyzed using graph 
theory, to describe overall characteristics of the network, which could be an 
interesting addition to the analysis138,139. Another interesting method could be 
source analysis to properly investigate the activity in specific brain centers related 
to analgesic response140. Such an analysis would not only help in developing the 
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personalized medicine algorithm, but also assist in understanding the underlying 
cause for heterogeneity in opioid response. 
 
10.2. EEG as a biomarker for opioid response 
Biomarkers are characteristics that can be objectively measured as an indicator for 
normal or pathological processes as well as pharmacological response to 
treatment15. Identification of opioid response phenotypes aim to identify sub-groups 
of patients, and tailor treatment for each sub-type15. Reliability of the biomarker is 
equally important as accuracy within personalized medicine but is unfortunately an 
area which is often overlooked within many areas of science141,142. EEG during cold 
pain appears more suitable for prediction of analgesic treatment outcome both in 
experimental pain models and in post-operative pain due to the higher prediction 
accuracy (Paper II and III). Furthermore, the spectral EEG content cold pain is 
reliable between days (Paper I) and provides similar results using the machine 
learning algorithm between days, both in terms of classification performance and in 
terms of the channels selected (Paper II).  
EEG assesses the neuronal activity at the scalp and has a relatively poor spatial 
accuracy compared to imaging methods143. Neuroimaging has been suggested as an 
important approach on the way to personalizing pain treatment18.  However, 
imaging methods would introduce substantial economic costs and logistical 
challenges, making it problematic to include as part of a personalized medicine 
approach. Though the spatial resolution limits the EEG in identifying the exact 
brain regions involved in a response, it is a low-cost method that could easily be 
brought to a patient bed-side. Furthermore, it has previously been shown to predict 
pain experience within individuals20, proving its utility for investigations at the 
individual level. 
Advances in the technical field is further improving the utility of EEG by moving 
away from the practice of establishing connection between electrode and scalp by 
electrode gel144. This practice requires scalp preparation and can introduce several 
problems, such as 1) loss of connection due to drying of electrode gel, 2) short-
circuiting of electrodes due to excessive use of gel, 3) pain/discomfort in patients as 
scalp preparation usually involves abrasion of the outer skin layer145. Furthermore, 
the main time in EEG recordings is consumed in these preparations145. However, in 
recent years dry electrodes have been developed with no requirement for electrode 
gel or skin preparation145,146. Such equipment would greatly reduce mounting times, 
further making EEG more attractive for fast, clinical measurements.  
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10.3. Response stratification 
When developing methods for personalized medicine it is important to have a gold 
standard for response in order to assess accuracy of the method and separate the 
opioid response from other factors that might influence analgesic effect. The most 
common threshold for clinical response to analgesic treatment is reduction of pain 
intensity by 30%. For QST models this threshold can be problematic as analgesic 
effect is generally lower55. This was also the case in paper II where the application 
of the traditional threshold for analgesic response to a clinically relevant dose 
(30mg) of morphine would have resulted in just one responder out of 39 subjects.  
Due to these limitations, the standard 30% threshold was not applied and a 
threshold was instead set at 5%. Since there is not definition of response for 
experimental pain models this was mostly based on methodological concerns to 
achieve balance between response groups, which is beneficial for machine learning 
methods when analyzing small data samples. Paper III investigated postoperative 
pain, for which the 30% threshold is not valid since there is no baseline pain 
measurement to compute pain reduction from. Therefore a response score based on 
several clinical pain measures which was employed in order to account for fact that 
both postoperative pain ratings and analgesic consumption will vary due to the 
postoperative patient controlled anesthesia (PCA)147. Ethical issues require that 
PCA is made available to patients after surgery in order to avoid insufficient 
analgesia147. This problem is one of the primary focus points for analgesic research, 
as it affects many analgesic studies148,149. A score integrating both analgesic 
consumption and perceived pain has been attempted150, but has failed to achieve 
widespread acceptance and as such validity of the method remains unknown16. 
Thus, a score based on pain ratings was developed to assess the level of response 
for each patient, resulting in a response rate of 65% which is in line with this type 
of procedure. The lack of opioid consumption as a factor in the response score 
could be a confounder in paper III, however since stratification based on opioid 
consumption did not result in higher accuracies it is likely not a major confounder. 
However, methods for establishing robust criteria for analgesic response are 
severely lacking within not just postoperative analgesia, but also experimental pain 
models and should be of continued focus within analgesic research. 
Paper III revealed a connection between preoperative pain severity and efficacy of 
postoperative pain management. Hence, higher severity of chronic pain grade, 
MPSS and higher levels of perceived pain during hip rotation was observed in non-
responders to postoperative opioid analgesia. This is in line with previous literature 
which indicates that preoperative pain strongly predicts acute postoperative 
pain2,151,152. However, since the response score in paper III was determined by the 
postoperative pain ratings, it will by extension also be related to the preoperative 
pain condition. Although this is an important factor in postoperative pain treatment, 
it also complicates identification of correct algorithm for prediction of analgesia, 
since the preoperative pain condition affects both the EEG as well as the 
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postoperative pain experience. This makes it hard to discern if the features found in 
the EEG represents the preoperative pain condition or a specific phenotype for 
opioid response. There are indications that the findings could be connected to an 
opioid response phenotype, since the discriminative features found in paper II 
(where subjects had no prior pain) where somewhat similar to the patient population 
in paper III. However, it is not possible to establish if this is the case in paper III, 
but would instead require a clinical study on a patient population with no chronic 
pain condition. 
Paper I and II investigated morphine while paper III investigated a combination 
treatment of oxycodone and piritramide. Different opioids may have different 
effects in the individual patients34, and even equi-potent opioid doses of different 
opioids can have widely different effects on the EEG activity44. Therefore, results 
using different opioids cannot be directly compared. Furthermore, paper III is 
further complicated by the inclusion of two opioids for analgesic treatment, as this 
introduces several sub-groups (responders to both opioids, non-responders to both 
and responders to just one opioid) into the analysis, which are impossible uncover 
in the analysis. However as III was an observational study with no possibility for 
altering analgesic treatment this could not be avoided. Since this could act as a 
major confound in the study, future studies should try and perform clinical 
investigations using just one opioid at a time, to avoid similar issues. 
 
10.4. Prediction of analgesic efficacy 
Prediction of analgesic effect holds great potential to improve pain treatment by 
individualizing treatment for each patient18. Beyond the increased suffering, 
inadequate pain treatment after surgery increases the chance of developing chronic 
pain153. Furthermore, opioid use is associated with serious safety concerns 
regarding abuse and addiction which is resulting in an increasing number of 
deaths154. Personalized treatment is therefore equally about identifying the right 
treatment as well as sparing patients from risks associated with inadequate 
treatment15,18.  
To date studies have focused on the use of QST models for prediction of analgesic 
effect and some results have been promising16. However, no single QST method has 
so far emerged as a golden standard and results have been variable16. Paper III 
investigated QST measures (heat, cold and pressure pain) performed before surgery 
for predictive capability, but found no connection to the post-operative analgesic 
effect. This could be connected to central sensitization due to the pre-existing 
painful condition, which opioids have limited efficacy against155.  
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Due to the pre-existing chronic pain condition patients in paper III were already on 
analgesic treatment prior to surgery. It is well know that analgesics affect the EEG39 
and therefore the preoperative medicine could have interfered with EEG recordings. 
However, as preoperative analgesic usage was relatively low the effect were likely 
minor. Even so, avoiding preoperative analgesic usage if possible is desirable for 
future studies.  
Chronic pain is known to be associated with impaired descending inhibition 
(assessed by CPM paradigms), an effect which could possibly imply that the system 
is already maximally engaged64,66. Lowered CPM response is also associated with 
opioid consumption after surgery156 and development of chronic pain157,158. This 
notion is supported by studies investigating the descending inhibition after the 
chronic pain has been relieved shows a return of function65. Paper III observed 
impaired descending inhibition in the osteoarthritis patients, meaning that their 
ability to regulate pain was compromised due to their pain condition. However, this 
was not a predictor of response to postoperative analgesia, but rather an overall 
condition for all patients. 
Conventional group-wise statistics have limitation in use for personalized medicine 
since they focus on detecting differences between groups rather than assessing the 
individual subject which is of major clinical interest, making machine learning 
more suitable159. Furthermore, machine learning method are able to assess multiple 
features simultaneously which is important for high-dimensional data such as EEG. 
This has been seen before in studies on analgesic effect, which found the effect 
reflected in the EEG based on a SVM classifier which assessed all EEG frequency 
bands simultaneously21. The previous findings are further confirmed in paper II and 
III which both showed that traditional group-wise statistics were unable to assess 
the differences between responders and non-responders to opioid analgesia, 
whereas machine learning methods enabled prediction of analgesic effect. 
The over-all accuracies for the predictions were 72% (paper II) and 65% (paper III). 
Positive predictive values were 70/75% (paper II) and 75% (paper III). Thus, if 
patients had been treated according to the machine learning results based on EEG 
prior to treatment, response rates would have been higher. In a personalized 
medicine scenario the remaining patients would then be treated with an alternative 
treatment although there was a higher degree of false negatives in paper III.  
However, in a personalized medicine scenario using EEG and machine learning to 
switch patients to an alternative treatment, the patients falsely classified as non-
responders could still respond to the alternative treatment. Unfortunately the 
response rate of an alternative treatment could not be determined due to study 
design limitations. Future work could attempt such studies, but only after consensus 
has been made on a model for predicting analgesic opioid response. 
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The features selected in paper II were predominantly frontal and central electrodes 
of the delta band while only one frontal electrode from the delta band was selected 
in paper III. There is a level of similarity between the two studies in that they both 
selected features from frontal delta electrodes. Some differences are present like the 
number of selected electrodes, but given the differences between the studies (e.g. 
population, experimental pain vs. clinical pain, etc.) and the fact that the drugs were 
not consistent makes differences in the selected features very likely. This could 
potentially be an advantage as the number of needed electrodes would decrease 
which would reduce time required for making a measurement.  
 
10.5. Clinical implications 
Personalized treatment targeting the individual patient and identifying optimal 
treatment strategies holds great promise for improving current analgesic treatments 
and reducing the rising abuse of opioids seen worldwide15,18. Most studies 
investigating prediction of opioid analgesic effect has utilized subjective QST 
models. However, no single QST model has been discovered which can be 
recommended for prediction of analgesia and large variations exist application of 
the QST models16. Neuroimaging has previously proved useful with regards to 
understanding pain processing and could therefore also prove valuable for 
personalized medicine18. However, neuroimaging methods are infeasible 
logistically and economically in a clinical algorithm. EEG is an objective 
measurement and has lower costs than neuroimaging methods but can still assess 
neurological activity in the brain and has been shown in papers II and III to contain 
information which could help predict response to opioid treatment. Although 
accuracy is likely still too low for clinical application, this poses an important first 
step for personalized pain medicine with EEG. Furthermore, the machine learning 
approach also opens up the possibility for including other features for prediction in 
the same analysis, such as QST measures, clinical parameters or genetic profiling.   
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Chapter 11. Conclusions 
This study marks the first investigations into objective biomarkers for prediction of 
opioid analgesia. We demonstrated the robustness of EEG as a biomarker and the 
ability to separate responders from non-responders in both healthy volunteers and 
patients scheduled to undergo total hip replacement surgery. The conclusions 
corresponding to each of the aims I-VI are presented below: 
 
11.1. Aim I 
To investigate the reliability of EEG over time to establish if the measurements 
would be sufficiently robust to use in personalized medicine (Paper I). 
For any use of EEG in personalized medicine, it is imperative that the derived EEG 
parameters remain relatively stable over time. This was achieved by investigating 
the reliability of EEG parameters in paper I. Overall EEG parameters had good 
reliability and therefore seems appropriate for use in a personalized medicine 
algorithm. This was also underlined in paper II where the results were repeated 
when using EEG recorded on two separate days from the same subjects. 
 
11.2. Aim II 
Analyze dynamics of the EEG and pain ratings during cold pain to gain further 
insight into pain processing during cold pain (Paper I). 
The analysis of the EEG revealed that the overall EEG activity was correlated to 
overall pain intensity from both the theta, beta3 and gamma bands. However, the 
dynamic analysis revealed that only the theta band was dynamic, and therefore 
likely to be more closely linked to the pain ratings, which during the cold pain are 
highly dynamic. Thus, dynamic analysis allowed for more specific information on 
pain processing during cold pain, and could be utilized in the future within pain 
research. 
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11.3. Aim III 
To establish if the EEG during rest or tonic cold pain is more suited for prediction 
of opioid analgesia (Paper I, II and III). 
EEG during tonic cold pain showed to be consistently superior to resting EEG, both 
in reliability and ability to discriminate between responders and non-responders. 
Thus tonic pain models seem to be more appropriate for future work using EEG in 
personalized medicine. 
11.4. Aim IV 
To compare a machine learning analysis approach to conventional group-based 
statistics in order to investigate if more sensitive prediction can be achieved (Paper 
II and III). 
A relatively new analysis method within clinical research was introduced based on 
machine learning and advanced feature selection in order to assess the individual 
subject without a priori assumptions about the data. This method proved to be 
superior to group-based statistics for separating responders to opioid analgesia from 
non-responders both in paper II and III.  
11.5. Aim V 
To explore if combination of several features in machine learning enables 
separation of responders and non-responders to morphine in healthy volunteers 
(Paper II). 
Machine learning enabled prediction of morphine analgesia based on EEG during 
cold pain recorded prior to drug administration. This prediction could be repeated 
using EEG during cold pain recorded on another day. The features selected for 
prediction suggest primarily the delta band contains information regarding the 
response to morphine. 
11.6. Aim VI 
To investigate if machine learning can be used to predict the analgesic efficacy in 
patients with postoperative pain (Paper III). 
The machine learning approach enabled prediction of postoperative analgesic effect 
from oxycodone and piritramide in patients undergoing total hip replacement. The 
delta band was again selected as the most predictive feature.   
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Chapter 12. Future perspectives 
The search for biomarkers associated with analgesic response is still ongoing and 
hold great potential for improving treatment of patients. This study has uncovered 
some interesting findings, but many questions still remain unanswered. In order to 
move the field forward, some areas of interest should be investigated: 
Clinical studies should be conducted to further determine consistency of the results 
presented in this thesis. Additionally, many of the confounding factors should as 
well as possible be avoided. This could include investigations into a patient 
population undergoing surgery much like in this thesis, but with minor alterations. 
Firstly, treatment should be attempted using only one opioid. This should preferably 
be a widely used and well-known opioid (such as morphine) to increase the clinical 
utility of investigations. Secondly, chronic pain introduces variability into the EEG 
which can interfere with measurements. To combat this problem clinical studies 
could be performed on patient populations undergoing surgery, but without pain 
prior to surgery. Therefore we are currently investigating ~60 patients undergoing 
surgical funnel chest repair. The patients undergoing this surgery are generally 
healthy, pain-free and opioid naïve males. Since there is no pre-existing pain 
condition and medication, many of confounders can be avoided and hopefully a 
clearer signal can be found. This would help in determining which features in the 
EEG are connected purely to the analgesic response to opioids.  
Of course personalized treatment should in the end also target chronic pain 
populations and therefore have to deal with these issues, and therefore we have 
conducted a multi-center study (ClinicalTrials.gov identifier: NCT02308306) on 
chronic pain patients at five centers throughout Europe and included 60 patients. 
The patients were all opioid naïve at the time of EEG recording, and follow-up was 
performed after 14 days to determine response to treatment. This study will 
investigate if any patterns can be found in the EEG and QST to predict analgesic 
effect in a chronic pain population. 
This thesis focused purely on the analgesic effect of opioids as an outcome of 
treatment. However, adverse effect is also an interesting aspect in opioid treatment 
and can in some cases be so severe that patients deem the treatment worse that pain 
and discontinue treatment. This was not investigated in the current thesis in order to 
limit the scope of investigations, but should be considered for future studies. It is 
possible that the methods presented in this thesis could be used for this same 
purpose and would help cast light on a different but important aspect of treatment. 
When properly investigated results from prediction of analgesic response could be 
combined with prediction of adverse effects to present clinicians with a more 
complete view of the consequences of a given treatment. 
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The methods presented in this PhD thesis are relatively new within clinical research 
which mostly relies on conventional statistics. The prospective usefulness of these 
methods are not confined to pain research, but could in theory be used in many 
applications as a tool for decision support. We have started one such study for 
grading the severity of hepatic encephalopathy. As the severity of the disease 
increases, patients brains start to be affected to a degree which could make them a 
danger e.g. in traffic. However, it is difficult for clinicians to detect when the 
patient is impaired and special precautions should be taken. EEG has shown some 
promise in detecting severity of disease, but more accurate detection is needed. Our 
analysis will incorporate EEG (226 patients with different grades of hepatic 
encephalography and 137 healthy volunteers) into machine learning to allow for 
simultaneous assessment of several EEG parameters, and hopefully increasing 
sensitivity. 
Machine learning can also be used for more simple measures than EEG, such as 
QST or clinical parameters. To illustrate this we analyzed 88 patients undergoing 
mastectomy for treatment of breast cancer for preoperative risk factors to develop 
postoperative chronic pain. Prior to surgery QST and clinical parameters were 
recorded and follow-up was made 6 months after surgery to establish who would go 
on to develop postoperative chronic pain. We analyzed the two groups and found 
simple two QST measures to be predict the development of chronic pain with a 
sensitivity and specificity of around 70 and 80%. These results, which are still 
under preparation for publishing, could pave the way for a simple test to establish 
which patients should be take special care of after surgery to prevent chronic pain 
developing. Furthermore, it shows the potential of machine learning within clinical 
research with simultaneous assessment of multiple parameters without any a priori 
assumptions. 
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